JP2011516511A5 - - Google Patents

Download PDF

Info

Publication number
JP2011516511A5
JP2011516511A5 JP2011503354A JP2011503354A JP2011516511A5 JP 2011516511 A5 JP2011516511 A5 JP 2011516511A5 JP 2011503354 A JP2011503354 A JP 2011503354A JP 2011503354 A JP2011503354 A JP 2011503354A JP 2011516511 A5 JP2011516511 A5 JP 2011516511A5
Authority
JP
Japan
Prior art keywords
stereoisomer
mixture
tautomer
proportions
atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011503354A
Other languages
English (en)
Japanese (ja)
Other versions
JP5485979B2 (ja
JP2011516511A (ja
Filing date
Publication date
Priority claimed from DE102008017590A external-priority patent/DE102008017590A1/de
Application filed filed Critical
Publication of JP2011516511A publication Critical patent/JP2011516511A/ja
Publication of JP2011516511A5 publication Critical patent/JP2011516511A5/ja
Application granted granted Critical
Publication of JP5485979B2 publication Critical patent/JP5485979B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011503354A 2008-04-07 2009-03-17 グルコピラノシド誘導体 Expired - Fee Related JP5485979B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102008017590A DE102008017590A1 (de) 2008-04-07 2008-04-07 Glucopyranosidderivate
DE102008017590.0 2008-04-07
PCT/EP2009/001946 WO2009124638A1 (de) 2008-04-07 2009-03-17 Glucopyranosidderivate

Publications (3)

Publication Number Publication Date
JP2011516511A JP2011516511A (ja) 2011-05-26
JP2011516511A5 true JP2011516511A5 (enExample) 2012-05-10
JP5485979B2 JP5485979B2 (ja) 2014-05-07

Family

ID=41051529

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011503354A Expired - Fee Related JP5485979B2 (ja) 2008-04-07 2009-03-17 グルコピラノシド誘導体

Country Status (9)

Country Link
US (1) US8399509B2 (enExample)
EP (1) EP2260051B1 (enExample)
JP (1) JP5485979B2 (enExample)
AU (1) AU2009235786B2 (enExample)
CA (1) CA2720586C (enExample)
DE (1) DE102008017590A1 (enExample)
ES (1) ES2394240T3 (enExample)
IL (1) IL208065A (enExample)
WO (1) WO2009124638A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010128152A1 (en) * 2009-05-07 2010-11-11 Novartis Ag Fused heterocyclic c-glycosides for the treatment of diabetes
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
US9034921B2 (en) * 2011-06-01 2015-05-19 Green Cross Corporation Diphenylmethane derivatives as SGLT2 inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9340521B2 (en) * 2013-03-18 2016-05-17 Green Cross Corporation Method for dual inhibition of SGLT1 and SGLT2 using diphenylmethane derivatives
WO2018013430A2 (en) 2016-07-12 2018-01-18 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus infection
US12419865B2 (en) 2018-12-06 2025-09-23 Arisan Therapeutics Inc. Compounds for the treatment of arenavirus infection
WO2025160910A1 (en) * 2024-02-01 2025-08-07 New Wish Biotechnology Wuxi Co., Ltd. Indazole compound and pharmaceutical composition, preparation method and use thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663336B1 (fr) 1990-06-18 1992-09-04 Adir Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US6068834A (en) 1994-03-04 2000-05-30 The Procter & Gamble Company Skin lightening compositions
EP0876379A1 (en) 1996-01-17 1998-11-11 Novo Nordisk A/S Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
ES2176600T3 (es) 1996-12-26 2002-12-01 Tanabe Seiyaku Co Derivado de la propiofenona y procedimientos para su preparacion.
RU2200161C2 (ru) 1996-12-31 2003-03-10 Др. Редди'З Рисерч Фаундейшн Новые производные азолидиндиона, способ их получения (варианты), фармацевтические композиции на их основе, способ предупреждения или лечения, способ снижения глюкозы и промежуточное соединение
EP0953357A1 (en) 1997-01-17 1999-11-03 Drug Delivery System Institute, Ltd. Nephrotropic drugs
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
JP2001510195A (ja) 1997-07-16 2001-07-31 ノボ ノルディスク アクティーゼルスカブ 縮合化1,2,4−チアジアジン誘導体、その調製及び使用
CO4970713A1 (es) 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
JP2000080041A (ja) 1998-03-09 2000-03-21 Tanabe Seiyaku Co Ltd 医薬組成物
US6221897B1 (en) 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19845405C2 (de) 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
JP2002542245A (ja) 1999-04-16 2002-12-10 ノボ ノルディスク アクティーゼルスカブ 置換イミダゾール、それらの製造および使用
EP1177187B1 (en) 1999-04-28 2007-07-25 Sanofi-Aventis Deutschland GmbH Di-aryl acid derivatives as ppar receptor ligands
WO2000064876A1 (en) 1999-04-28 2000-11-02 Aventis Pharma Deutschland Gmbh Tri-aryl acid derivatives as ppar receptor ligands
EP1175421A1 (en) 1999-04-30 2002-01-30 Neurogen Corporation 9H-PYRIMIDO[4,5-b]INDOLE DERIVATIVES: CRF1 SPECIFIC LIGANDS
GB9911863D0 (en) 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
ATE333448T1 (de) 1999-06-18 2006-08-15 Merck & Co Inc Arylthiazolidinedione und aryloxa zolidinedion- derivate
DE60004066T2 (de) 1999-07-29 2004-04-15 Eli Lilly And Co., Indianapolis Benzofurylpiperazine: 5-ht2c serotoninrezeptor agonisten
BRPI0013667B8 (pt) 1999-08-31 2021-05-25 Kissei Pharmaceutical derivados de glucopiranosiloxipirazol, composições medicinais contendo os mesmos e seus intermediários na produção deles
DE50011035D1 (de) 1999-09-01 2005-09-29 Aventis Pharma Gmbh Sulfonylcarboxamidderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
CZ20023023A3 (cs) 2000-03-17 2003-04-16 Kissei Pharmaceutical Co., Ltd. Glukopyranosyloxybenzylbenzenové deriváty, léčivé směsi obsahující tyto látky a meziprodukty pro přípravu derivátů
US6683056B2 (en) 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
US6555519B2 (en) 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
WO2001083451A1 (en) 2000-04-28 2001-11-08 Asahi Kasei Kabushiki Kaisha Novel bicyclic compounds
CA2408486A1 (en) 2000-05-11 2001-11-15 Bristol-Myers Squibb Company Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
CA2410597A1 (en) 2000-05-30 2001-12-06 Merck & Co., Inc. Melanocortin receptor agonists
AU2001268718B2 (en) 2000-06-29 2006-01-05 Abbott Laboratories Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents
EP1329456B1 (en) 2000-09-29 2006-08-09 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same
ES2337127T3 (es) 2000-11-02 2010-04-21 Ajinomoto Co., Inc. Nuevos derivados de pirazol y remedios contra la diabetes que los contienen.
CA2429833A1 (en) 2000-11-30 2002-06-06 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof
WO2002068439A1 (fr) 2001-02-26 2002-09-06 Kissei Pharmaceutical Co., Ltd. Derives de glycopyranosyloxypyrazole et utilisation medicinale de ceux-ci
US7294618B2 (en) 2001-02-27 2007-11-13 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivatives and medicinal use thereof
US20030045553A1 (en) 2001-04-04 2003-03-06 Bussolari Jacqueline C. Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators
WO2002080935A1 (en) 2001-04-04 2002-10-17 Ortho Mcneil Pharmaceutical, Inc. Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators
JP4436129B2 (ja) 2001-08-31 2010-03-24 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ジアリールシクロアルキル誘導体、その製造法及びppar−活性剤としてのその使用
DE10258007B4 (de) 2002-12-12 2006-02-09 Sanofi-Aventis Deutschland Gmbh Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
DE10258008B4 (de) 2002-12-12 2006-02-02 Sanofi-Aventis Deutschland Gmbh Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
PL1609785T3 (pl) * 2003-03-14 2016-07-29 Astellas Pharma Inc Pochodne c-glikozydowe i ich sole
EP1679965A4 (en) * 2003-08-01 2009-05-27 Janssen Pharmaceutica Nv SUBSTITUTED ANELLIERED HETEROCYCLIC C-GLYCOSIDES
CA2557269C (en) * 2004-03-04 2012-12-04 Kissei Pharmaceutical Co., Ltd. Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof
SE533267C2 (sv) 2008-12-16 2010-08-03 Sandvik Intellectual Property Skärkit, förfarande för tillverkning av skär, samt ett ur ett skärkit avskilt skär

Similar Documents

Publication Publication Date Title
JP2011516511A5 (enExample)
RU2445312C2 (ru) ПРОИЗВОДНЫЕ 2-МЕТИЛМОРФОЛИН ПИРИДО-, ПИРАЗО- И ПИРИМИДО-ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ mTOR
JP2010524932A5 (enExample)
JP2013508279A5 (enExample)
JP2011504903A5 (enExample)
JP2007529421A5 (enExample)
JP2013542247A5 (enExample)
JP2009504763A5 (enExample)
JP2009507896A5 (enExample)
JP2007538024A5 (enExample)
JP2012505871A5 (enExample)
CN110776453A (zh) 用于治疗沙粒病毒感染的抗病毒药物
UA109421C2 (uk) Фармацевтична композиція, яка містить ліганди сигма-рецептора
JP2012504126A5 (enExample)
UY30809A1 (es) Derivados de n-[3-[4-fenil)piperidin-1-carbonil]fenil]sulfonamidas sustituidas, procesos de preparacion y aplicaciones
RU2015118581A (ru) Лиофилизированные препараты мелфалана флуфенамида
JP2013518832A5 (enExample)
NZ590355A (en) Stat3 inhibitor containing quinolinecarboxamide derivative as active ingredient
JP2017531619A5 (enExample)
JP2019510027A5 (enExample)
JP2011506501A5 (enExample)
JP2018502101A5 (enExample)
RU2011133128A (ru) Противоопухолевые соединения дигидропиран-2-она
RU2008145714A (ru) Пуриновые производные в качестве активатора аденозинового рецептора
GEP20125548B (en) New dihidroindolone compounds, a process for its preparation and pharmaceutical compositions containing them